Effective 1 de enero de 2023, BCBSRI will cover the infliximab biosimilar products, Avsola and Inflectra, in place of Remicade. If you currently have patients with an authorization for Remicade, you and the member will receive a letter regarding this change. You will need to speak with your patients about switching to Avsola or Inflectra, prior to 1 de enero de 2023.

If you believe it is medically necessary for your patient to continue on Remicade after 1 de enero de 2023, you will need to complete a Coverage Exception form and submit it to Prime Therapeutics beginning 1 de enero de 2023. 

If you have any additional questions, or would like more information pertaining to letters sent, please contact providerrelations@bcsri.org.